1. USP13 overexpression in BMSCs enhances anti-apoptotic ability and guards against methylprednisolone-induced osteonecrosis in rats.
- Author
-
Jiang Y, Fan X, Yu Y, Ge H, Liu C, Zhang Y, Yu L, Yin W, and Zhou Z
- Subjects
- Animals, Rats, Femur Head Necrosis chemically induced, Femur Head Necrosis pathology, Femur Head Necrosis metabolism, Femur Head Necrosis genetics, Femur Head Necrosis therapy, Rats, Sprague-Dawley, Male, Ubiquitin-Specific Proteases metabolism, Ubiquitin-Specific Proteases genetics, Mesenchymal Stem Cell Transplantation methods, Osteonecrosis pathology, Osteonecrosis metabolism, Osteonecrosis genetics, Osteonecrosis chemically induced, Apoptosis drug effects, Methylprednisolone pharmacology, Mesenchymal Stem Cells metabolism
- Abstract
Methylprednisolone (MPS) use is linked to increased cases of osteonecrosis of the femoral head (ONFH). Bone marrow mesenchymal stem cells (BMSCs) have shown potential for treating MPS-induced ONFH, but their effectiveness is limited by high apoptosis rates post-transplantation. We developed a pretreatment strategy for BMSCs to improve their viability. In a rat model of MPS-induced ONFH, we evaluated the effects of USP13 overexpression in BMSCs through micro-CT, HE staining, and TUNEL staining. USP13-overexpressing BMSCs significantly reduced ONFH severity compared to plain BMSCs and direct lentivirus injection. USP13 also protected BMSCs from MPS-induced apoptosis by modulating PTEN and reducing AKT phosphorylation. This led to decreased expression of apoptotic genes and proteins in USP13-overexpressing BMSCs. Our findings highlight USP13 as a promising target for enhancing BMSC survival and efficacy in treating MPS-induced ONFH., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2025
- Full Text
- View/download PDF